tirzepatide surpass cvot SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I π‘ New insight in diabetes
Description
- COA verified Retatrutide for batch consistency
Several studies have demonstrated reversal of weight loss and other cardiometabolic benefits after patients discontinue GLP-1RAs
Improvement in Quality of Life
Anemia of chronic disease is managed by treating the underlying condition and using erythropoiesis-stimulating agents if needed
Scientifically Designed for Metabolic Reset & GLP-1 Activation
